This paper is only available as a PDF. To read, Please Download here.
Background: Several pharmacologic and nonpharmacologic interventions are available for the treatment of symptoms of overactive bladder (OAB). The relationship between type of initial intervention and subsequent symptom improvement and resource utilization has not been explored in detail.
Objective: The purpose of this study was to assess (1) the proportion of patients continuing with their initially prescribed treatment for OAB 3 and 6 months after the initial evaluation and (2) the relationship between actual treatment patterns, symptom improvement, and number of physician office visits.
Methods: A total of 31 physicians enrolled patients with OAB for this 6-month prospective, observational study. Baseline data on OAB symptom severity and OAB management strategies were obtained and initial treatment(s) were prescribed by physicians during a routine office visit. Follow-up data on symptom changes, treatment changes, number of physician office visits, and the frequency of absorbent pad use were collected via telephone interviews with patients 3 and 6 months after the initial visit. Stepwise logistic regression was used to assess the relationship between patient characteristics, prescription of medication, and symptom improvement.
Results: A total of 213 patients were enrolled; 122 (57.3%) and 100 (46.9%) patients provided follow-up data at the 3-month and 6-month assessments, respectively. The mean age was 61.2 years; 85.2% of patients were female, and 77.7% were white. OAB symptom improvement was significantly related to being prescribed medication (odds ratio [OR], 4.3; 95% CI, 1.8–9.9) and the mean number of daily leakage incidents at baseline (OR, 3.2; 95% CI, 1.2–8.4). Although patients who were prescribed drugs at baseline tended to have fewer physician office visits and were less likely to be prescribed nondrug interventions than patients who were not treated initially with drugs, these differences were not statistically significant.
Conclusions: Pharmacologic treatment for symptoms of OAB appears to be associated with greater symptom improvement than nonpharmacologic treatment. Larger studies of experimental design are needed to determine whether patients treated with medication use fewer nondrug interventions and require fewer physician office visits than patients treated without medication.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Clinical Therapeutics
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- The Overactive Bladder: A Widespread and Treatable Condition. Eik Sparre Medical AB, Stockholm1998
- Introduction: Overactive bladder and its treatments.Urology. 2000; 55 (Suppl 5A): 1-2
- Definition of overactive bladder and epidemiology of urinary incontinence.Urology. 1997; 50 (Suppl 6A): 4-14
- Urinary incontinence in women: Its prevalence and its management in a health promotion clinic.Br J Gen Pract. 1994; 44: 149-152
- Medically recognized urinary incontinence and risks of hospitalization, nursing home admission and mortality.Age Ageing. 1997; 26: 367-374
- Urinary incontinence: Does it increase risk for falls and fractures?.J Am Geriatr Soc. 2000; 48: 721-725
- Proceedings.J Am Geriatr Soc. 1990; 38 (Bethesda, Maryland, October 3–5, 1988): 263-386
- The impact of urge urinary incontinence on quality of life: Importance of patients' perspective and explanatory style.J Am Geriatr Soc. 1998; 46: 683-692
- The effects of urinary incontinence in women.Int Rehabil Med. 1982; 4: 9-14
- Overactive bladder significantly affects quality of life.Am J Managed Care. 2000; 6 (Suppl 11): S580-S590
- Clinical Practice Guideline Number 2, Urinary Incontinence in Adults: Acute and Chronic Management. US Dept of Health and Human Services, Agency for Health Care Policy and Research, Rockville, Md1996 (AHCPR publication 96-0682)
- Preference, compliance and initial outcome of therapeutic options chosen by female patients with urinary incontinence.J Urol. 1995; 154: 1727-1730
- A pilot study to determine reasons for patient withdrawal from a pelvic muscle rehabilitation program for urinary incontinence.J Appl Gerontol. 1999; 18: 379-396
- Effectiveness of behavioral therapy to treat incontinence in homebound older adults.J Am Geriatr Soc. 1999; 47: 309-318
- Pelvic muscle exercise for stress urinary incontinence in elderly women.J Am Geriatr Soc. 1991; 39: 785-791
- Efficacy of pelvic floor muscle exercises in women with stress, urge, and mixed urinary incontinence.Am J Obstet Gynecol. 1996; 174: 120-125
- Biofeedback for the treatment of stress and urge incontinence.J Urol. 1995; 153: 641-643
- IMS National Prescription Audit Plus™. IMS, Plymouth Meeting, PaJanuary 1997 and April 2000
- Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence.J Urol. 1999; 161: 1809-1812
- Tolterodine, a new muscarinic agent: As effective but better tolerated than oxybutynin in patients with an overactive bladder.Br J Urol. 1998; 81: 801-810
- Dry mouth with conventional and controlled-release oxybutynin in urinary incontinence.Obstet Gynecol. 2000; 95: 718-721
- Electrical stimulation for the treatment of urinary incontinence.Urology. 1998; 51 (Suppl 2A): 24-26
- Combined behavioral and drug therapy for urge incontinence in older women.J Am Geriatr Soc. 2000; 48: 370-374
- Behavioral intervention for community-dwelling individuals with urinary incontinence.Urology. 1998; 51 (Suppl 2A): 30-34
- A health related quality of life measure for use in patients with urge urinary incontinence: A validation study.Qual Life Res. 1999; 8: 337-344
- Factors associated with clinical assessment of overactive bladder and selection of treatment.Clin Ther. 2001; 23: 1542-1551
Accepted: January 16, 2002
© 2002 Published by Elsevier Inc.